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Pulmonary embolism is a common condition with a high mortality. We describe a previously healthy 68-year-old male
who suﬀered three pulmonary embolisms during a short period of time, including two embolisms while on anticoagulant
treatment. This paper illustrates three important points. (1) The importance of optimal anticoagulant treatment in the prevention
of pulmonary embolism reoccurrence. (2) The beneﬁt of immediate accessibility to echocardiography in the handling of
haemodynamicallyunstablepatientswithanunknownunderlyingcause.(3)Thrombolytictreatmentshouldalwaysbeconsidered
and may be life-saving in patients with cardiac arrest suspected to be caused by pulmonary embolism.
1.Introduction
Pulmonary embolism (PE) is a common cardiovascular
emergencyoftencausedbydeepveinthrombosisinthelower
extremities [1, 2]. Three-month mortality in hospitalised
patients with PE is almost 20% [3] and is especially high
in patients with compromised circulation; in these patients
thrombolysis should be considered [2, 4]. Furthermore,
unfractionated or low-molecular-weight heparin (LMWH)
is used for at least ﬁve days, and, simultaneously, oral
anticoagulation with a vitamin K antagonist (VKA) is ini-
tiated. LMWH is stopped when the international normalised
ratio (INR) has been within the therapeutic level of 2.0-3.0
for at least two days [2, 5]. The risk of recurrent venous
thromboembolism (VTE) is highest during the ﬁrst 6 to
12 months, but oral VKA can be expected to decrease
recurrence rate to about 1% per year [5]. The duration of
VKA treatment is usually 3–12 months and is based on an
individual estimate of recurrence and bleeding risk [4].
2.CaseReport
A previously healthy 68-year-old employed, non-smoking
62kg male was admitted with worsening shortness of breath
during one day. Nine weeks earlier, the patient had been
admitted with cardiac arrest caused by a central PE, which
was surgically removed. The patient had been discharged
with VKA treatment (warfarin), and since then the INR had
been between 2 and 3, as conﬁrmed until nine days prior to
the present admission, when the INR was 2.2. However, on
admission the INR was only 1.7.
The patient was in acute distress with a blood pressure
of 60/40mmHg and a peripheral saturation of 80% despite
high-ﬂowoxygenwithareservoirmask.Electrocardiography
showed a discrete SIQIIITIII pattern and incomplete right
bundle branch block (Figure 1). Acute echocardiography
showed increased pulmonary pressure with tricuspid regur-
gitation with a pressure gradient of 50mmHg. The patient
received thrombolysis on suspicion of a new PE. Heparin
infusion was initiated concurrently and was then changed
to subcutaneous LMWH (dalteparin 6000IU twice daily).
A computed tomography (CT) scan raised suspicion of a
malignant inﬁltrate in the left lung. The following day the
patient had a fever (38.5◦C) and a dry cough, and antibiotic
treatment was started on suspicion of pneumonia. Five days
after thrombolysis, echocardiography showed normalised
pulmonary pressure.
One week after admission, the patient was started on
broad-spectrum antibiotics due to persistent fever (38–
38.5◦C) and rising inﬂammatory markers. The patient had2 Case Reports in Medicine
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Figure 1: Electrocardiogram on admission.
a near-syncope and now complained over worsening short-
nessofbreathandaleft-sidedsharp,stabbingpainonbreath-
ing. The patient had a respiratory rate of 32, a peripheral
saturation of 75% (3 litres oxygen ﬂow), blood pressure was
80/50mmHg, and the pulse was 105. An electrocardiogram
showedsinusrhythmandarightbundlebranchblock,which
was now complete (Figure 2). Blood gas analysis showed a
fully compensated metabolic acidosis, no hypoxaemia, slight
hypocapnia, and lactate 8.5mmol/L. Treatment with high-
ﬂow oxygen and aggressive ﬂuid resuscitation was initiated;
this normalised the patient’s symptoms, vital signs, and
blood gas analysis during 15 minutes. However, after a few
hours,thepatientonceagaindeterioratedresultingincardiac
arrest. Initially, the patient had pulseless electrical activity,
and advanced resuscitation was initiated. After 15 minutes
with nonshockable rhythms, resuscitation was stopped.
An autopsy showed that a massive central PE was the
cause of death, and, additionally, cor pulmonale and a left-
sided pulmonary infarction were found. Importantly, there
were no signs of malignancy, deep venous thrombosis, or
pneumonia.
3. Discussion
PE should be suspected in all patients who present with new
or worsening dyspnoea, chest pain, or hypotension.
In haemodynamically stable patients, the ﬁrst step is to
assess the clinical probability of PE, which, for example,
can be achieved with the Wells score [2]. In patients with
low or intermediate clinical probability, a normal D-dimer
practically rules out PE, whereas an increased D-dimer
warrants further testing. Patients with a high clinical prob-
ability should undergo multidetector CT scan. A ventilation-
perfusionscanisanalternativein patients allergictocontrast
media or patients with renal failure.
In haemodynamically unstable patients, a multidetector
CT scan should be performed. If this is not immediately
available or if the patient’s condition is too critical, an echo-
cardiography should be performed. If signs of increased
pulmonary pressure are observed, thrombolytic therapy may
be considered according to guidelines [2, 6].
This case report illustrates three important points:
(1) The importance of optimal anticoagulant treatment
in the prevention of PE recurrence.
(2) The beneﬁt of immediate accessibility to echocardio-
graphy in the handling of haemodynamically unsta-
ble patients with an unknown underlying cause. In
this case the presumably optimal anticoagulant treat-
ment gave the wrong impression with regard to the
underlying cause. An echocardiographic observation
of recurrent increased pulmonary pressure would
have suggested recurrent PE instead of severe septi-
caemia.
(3) Thrombolysis should always be considered and may
belife-savinginpatientswithcardiacarrestsuspected
to be caused by PE [7].
Risk factors for PE include reversible (surgery, immo-
bilisation, and pregnancy/postpartum) and nonreversible
(cancer and congenital or acquired thrombophilia) factors,
but many cases are idiopathic/unprovoked [5, 8]. The riskCase Reports in Medicine 3
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Figure 2: Electrocardiogram 1 week after admission.
of recurrence is low in provoked PE (reversible factors) but
is moderate to high in patients with nonreversible factors,
particularly in patients with idiopathic PE [9].
The patient’s aggressive thrombogenicity suggested the
existence of an underlying malignancy which was, however,
ruled out by autopsy. There was no family history of VTE,
and, if the patient had had an inherited thrombophilia, the
patient’s ﬁrst VTE would most probably have occurred at a
younger age. On the other hand, antiphospholipid syndrome
cannot be deﬁnitively excluded as a possible cause of the
recurrent PE [5, 9, 10]. Postmortem testing for throm-
bophilia was not performed because the patient did not have
children, and a positive ﬁnding would not have had any
direct consequences.
IntherarecaseofrecurrentPE,despiteadequatesystemic
anticoagulation, an underlying cause must be identiﬁed if
possible, and the following treatment options considered.
(1) Increase the target INR to 2.5–3.5, acknowledging
that this may increase bleeding risk.
(2) Insert an inferior vena cava ﬁlter permanently or
a retrievable ﬁlter temporarily. Only a few widely
accepted indications for this procedure exist, such
as absolute contraindication to systemic anticoagula-
tion and failure of systemic anticoagulation in case of
acute proximal venous thrombosis [4]. Importantly,
complications of inferior vena cava ﬁlters are com-
mon [2].
(3) In a case with diﬃculty in achieving the target INR,
the use of newer anticoagulants (dabigatran etexilate,
apixaban, or rivaroxaban) or LMWH might be con-
sidered.
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